GlassScriptPhysician profile
Tuan A Pham
NPI 1134163793
$22,875.10
in general payments reported to CMS, 2019-2025
29 companies · $6,782 in 2025
The $6,782 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $1,031 · 2021: $1,404 · 2022: $1,572 · 2023: $4,369 · 2024: $6,367 · 2025: $6,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $12K · Food and Beverage: $5,365 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $12,133.33 |
| Food and Beverage | $5,364.91 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $12,301.59 | 2023-2025 | Venacure 1470 Pro, Venacure 1470 Pro |
| Novartis Pharmaceuticals Corporation | $1,362.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,215.82 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $1,174.92 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $1,029.85 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Farapulse, Resonate El Icd Vr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $950.76 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $694.70 | 2019-2025 | Farxiga |
| Amgen INC. | $667.45 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $592.70 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $572.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $439.63 | 2021-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $401.09 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $264.28 | 2019-2025 | Lifevest |
| Cardiovascular Systems INC. | $208.87 | 2019-2023 | Diamondback Coronary |
| Amarin Pharma, INC. | $204.81 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $156.65 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $127.89 | 2022 | |
| Novo Nordisk INC | $123.27 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $49.65 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $49.03 | 2024 | Arcalyst |
| Philips North America LLC | $46.98 | 2019-2022 | |
| Cathworks, INC. | $46.64 | 2019 | |
| Glaxosmithkline, LLC. | $44.93 | 2019 | |
| Ironwood Pharmaceuticals, INC | $38.92 | 2022 | |
| Medtronic Vascular, INC. | $35.68 | 2019-2020 | |
| Chiesi USA, INC. | $25.74 | 2022 | |
| Baxter Healthcare | $19.49 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Celgene Corporation | $14.74 | 2024 | Camzyos |
| Abbott Laboratories | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuan Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.